Publisher: John Wiley & Sons Inc
E-ISSN: 1555-2039|236|2|219-228
ISSN: 0022-3417
Source: THE JOURNAL OF PATHOLOGY, Vol.236, Iss.2, 2015-06, pp. : 219-228
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
AbstractBCR–JAK2 is an infrequent gene fusion found in chronic/acute, myeloid/lymphoid Philadelphia chromosome‐negative leukaemia. In this study, we demonstrated that in vivo expression of BCR–JAK2 in mice induces neoplasia, with fatal consequences. Transplantation of BCR–JAK2 bone marrow progenitors promoted splenomegaly, with megakaryocyte infiltration and elevated leukocytosis of myeloid origin. Analysis of peripheral blood revealed the presence of immature myeloid cells, platelet aggregates and ineffective erythropoiesis. A possible molecular mechanism for these observations involved inhibition of apoptosis by deregulated expression of the anti‐apoptotic mediator Bcl‐xL and the serine/threonine kinase Pim1. Together, these data provide a suitable in vivo molecular mechanism for leukaemia induction by BCR–JAK2 that validates the use of this model as a relevant preclinical tool for the design of new targeted therapies in Philadelphia chromosome‐negative leukaemia involving BCR–JAK2‐driven activation of the JAK2 pathway. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Related content
JAK2 and MPL Mutations in Myeloproliferative Neoplasms
Acta Haematologica, Vol. 119, Iss. 4, 2008-06 ,pp. :
Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders
Pathophysiology of Haemostasis and Thrombosis, Vol. 36, Iss. 3-4, 2009-01 ,pp. :